TP
Tempest Therapeutics, Inc.
TPST · NASDAQ
$0.97 +2.72% (+$0.03)
1M -6.92%
Market Cap $14.2M
P/E Ratio -
Div. Yield -
ROE 1,270.11%
Bulios Fair Price
$1.15
18.8% upside
Current Price
$0.97
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TPST is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 28.33%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 628.18%
Asset turnover 0.00x
ROE 1,270.11%
Debt
0 /100
High Current ratio 0.38x
Int. coverage -1,759.91x
Debt/Equity N/A
Stability
19 /100
Unstable Beta -1.66x
Profitable years 0
EPS volatility 203.84%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TPST
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Angel
Employees
4
Headquarters
Brisbane
Upcoming events
04 NOV
Earnings
Upcoming earnings report